The stock of Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has decreased by -14.13 when compared to last closing price of 3.48. Despite this, the company has experienced a -15.11% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-12 that HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-8 reverse stock split at 5:00 p.m. Eastern Time, on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Salarius’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X404 and the Company’s existing trading symbol “SLRX.”
Is It Worth Investing in Salarius Pharmaceuticals Inc (NASDAQ: SLRX) Right Now?
The 36-month beta value for SLRX is at 0.96. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The average trading volume for SLRX on June 20, 2024 was 17.87K shares.
SLRX’s Market Performance
SLRX’s stock has seen a -15.11% decrease for the week, with a -24.46% drop in the past month and a -43.28% fall in the past quarter. The volatility ratio for the week is 21.13%, and the volatility levels for the past 30 days are at 11.23% for Salarius Pharmaceuticals Inc The simple moving average for the last 20 days is -18.12% for SLRX stock, with a simple moving average of -39.33% for the last 200 days.
Analysts’ Opinion of SLRX
Many brokerage firms have already submitted their reports for SLRX stocks, with Ladenburg Thalmann repeating the rating for SLRX by listing it as a “Buy.” The predicted price for SLRX in the upcoming period, according to Ladenburg Thalmann is $3.80 based on the research report published on April 27, 2020 of the previous year 2020.
SLRX Trading at -21.94% from the 50-Day Moving Average
After a stumble in the market that brought SLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.06% of loss for the given period.
Volatility was left at 11.23%, however, over the last 30 days, the volatility rate increased by 21.13%, as shares sank -25.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.03% lower at present.
During the last 5 trading sessions, SLRX fell by -15.11%, which changed the moving average for the period of 200-days by -57.55% in comparison to the 20-day moving average, which settled at $3.60. In addition, Salarius Pharmaceuticals Inc saw -42.53% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLRX
The total capital return value is set at -2.51. Equity return is now at value -193.68, with -119.38 for asset returns.
Based on Salarius Pharmaceuticals Inc (SLRX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -94.4.
Currently, EBITDA for the company is -12.88 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.91.
Conclusion
In conclusion, Salarius Pharmaceuticals Inc (SLRX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
